Literature DB >> 16020800

Derivation and validation of a prognostic model for pulmonary embolism.

Drahomir Aujesky1, D Scott Obrosky, Roslyn A Stone, Thomas E Auble, Arnaud Perrier, Jacques Cornuz, Pierre-Marie Roy, Michael J Fine.   

Abstract

RATIONALE: An objective and simple prognostic model for patients with pulmonary embolism could be helpful in guiding initial intensity of treatment.
OBJECTIVES: To develop a clinical prediction rule that accurately classifies patients with pulmonary embolism into categories of increasing risk of mortality and other adverse medical outcomes.
METHODS: We randomly allocated 15,531 inpatient discharges with pulmonary embolism from 186 Pennsylvania hospitals to derivation (67%) and internal validation (33%) samples. We derived our prediction rule using logistic regression with 30-day mortality as the primary outcome, and patient demographic and clinical data routinely available at presentation as potential predictor variables. We externally validated the rule in 221 inpatients with pulmonary embolism from Switzerland and France. MEASUREMENTS: We compared mortality and nonfatal adverse medical outcomes across the derivation and two validation samples. MAIN
RESULTS: The prediction rule is based on 11 simple patient characteristics that were independently associated with mortality and stratifies patients with pulmonary embolism into five severity classes, with 30-day mortality rates of 0-1.6% in class I, 1.7-3.5% in class II, 3.2-7.1% in class III, 4.0-11.4% in class IV, and 10.0-24.5% in class V across the derivation and validation samples. Inpatient death and nonfatal complications were <or= 1.1% among patients in class I and <or= 1.9% among patients in class II.
CONCLUSIONS: Our rule accurately classifies patients with pulmonary embolism into classes of increasing risk of mortality and other adverse medical outcomes. Further validation of the rule is important before its implementation as a decision aid to guide the initial management of patients with pulmonary embolism.

Entities:  

Mesh:

Year:  2005        PMID: 16020800      PMCID: PMC2718410          DOI: 10.1164/rccm.200506-862OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  36 in total

1.  A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.

Authors:  G Simonneau; H Sors; B Charbonnier; Y Page; J P Laaban; R Azarian; M Laurent; J L Hirsch; E Ferrari; J L Bosson; D Mottier; B Beau
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

2.  A prediction rule to identify low-risk patients with heart failure.

Authors:  Thomas E Auble; Margaret Hsieh; William Gardner; Gregory F Cooper; Roslyn A Stone; Julie B McCausland; Donald M Yealy
Journal:  Acad Emerg Med       Date:  2005-06       Impact factor: 3.451

3.  A prediction rule to identify low-risk patients with pulmonary embolism.

Authors:  Drahomir Aujesky; D Scott Obrosky; Roslyn A Stone; Thomas E Auble; Arnaud Perrier; Jacques Cornuz; Pierre-Marie Roy; Michael J Fine
Journal:  Arch Intern Med       Date:  2006-01-23

4.  Pulmonary embolism as a cause of cardiac arrest: presentation and outcome.

Authors:  I Kürkciyan; G Meron; F Sterz; K Janata; H Domanovits; M Holzer; A Berzlanovich; H C Bankl; A N Laggner
Journal:  Arch Intern Med       Date:  2000-05-22

5.  Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection.

Authors:  P S Wells; M J Kovacs; J Bormanis; M A Forgie; D Goudie; B Morrow; J Kovacs
Journal:  Arch Intern Med       Date:  1998-09-14

6.  Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism.

Authors:  Drahomir Aujesky; Kenneth J Smith; Jacques Cornuz; Mark S Roberts
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

7.  Altered mental status: evaluation and etiology in the ED.

Authors:  William Kanich; William J Brady; J Stephen Huff; Andrew D Perron; Christopher Holstege; George Lindbeck; C Thomas Carter
Journal:  Am J Emerg Med       Date:  2002-11       Impact factor: 2.469

8.  Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism.

Authors:  Susan Murin; Patrick S Romano; Richard H White
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

9.  Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty.

Authors:  R H White; P S Romano; H Zhou; J Rodrigo; W Bargar
Journal:  Arch Intern Med       Date:  1998-07-27

10.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

Authors:  H R Büller; B L Davidson; H Decousus; A Gallus; M Gent; F Piovella; M H Prins; G Raskob; A E M van den Berg-Segers; R Cariou; O Leeuwenkamp; A W A Lensing
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

View more
  196 in total

1.  Prognostic significance of multidetector computed tomography in normotensive patients with pulmonary embolism: rationale, methodology and reproducibility for the PROTECT study.

Authors:  David Jiménez; José Luis Lobo; Manuel Monreal; Remedios Otero; Roger D Yusen
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

2.  Percutaneous circulatory support in a patient with cardiac arrest due to acute pulmonary embolism.

Authors:  Jürgen Leick; Christoph Liebetrau; Sebastian Szardien; Matthias Willmer; Johannes Rixe; Holger Nef; Andreas Rolf; Christian Hamm; Helge Möllmann
Journal:  Clin Res Cardiol       Date:  2012-06-12       Impact factor: 5.460

3.  Treating pulmonary embolism at home?

Authors:  Mari Ega; Kate Rowland
Journal:  J Fam Pract       Date:  2012-06       Impact factor: 0.493

4.  Challenging pulmonary embolism - A new generation of oral anticoagulants.

Authors:  Sérgio Barra; Luís Paiva; Rui Providência
Journal:  J Thorac Dis       Date:  2012-06-01       Impact factor: 2.895

Review 5.  A narrative review of red blood cell distribution width as a marker for pulmonary embolism.

Authors:  Lindsay Hammons; Jason Filopei; David Steiger; Eric Bondarsky
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

6.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

7.  Troponin I and right ventricular dysfunction for risk assessment in patients with nonmassive pulmonary embolism in the Emergency Department in combination with clinically based risk score.

Authors:  Vittorio Palmieri; Giovanni Gallotta; Domenico Rendina; Silvana De Bonis; Vittorio Russo; Alfredo Postiglione; Stefania Martino; Matteo Nicola Dario Di Minno; Aldo Celentano
Journal:  Intern Emerg Med       Date:  2008-02-13       Impact factor: 3.397

8.  Impella RP Support and Catheter-Directed Thrombolysis to Treat Right Ventricular Failure Caused by Pulmonary Embolism in 2 Patients.

Authors:  Mohamed Shokr; Ahmed Rashed; Ashraf Mostafa; Tamam Mohamad; Theodore Schreiber; Mahir Elder; Amir Kaki
Journal:  Tex Heart Inst J       Date:  2018-06-01

9.  Right ventricular dysfunction is superior and sufficient for risk stratification by a pulmonary embolism response team.

Authors:  Yu Lin Chen; Colin Wright; Anthony P Pietropaoli; Ayman Elbadawi; Joseph Delehanty; Bryan Barrus; Igor Gosev; David Trawick; Dhwani Patel; Scott J Cameron
Journal:  J Thromb Thrombolysis       Date:  2020-01       Impact factor: 2.300

10.  Racial differences in 30-day mortality for pulmonary embolism.

Authors:  Said A Ibrahim; Roslyn A Stone; D Scott Obrosky; Jennifer Sartorius; Michael J Fine; Drahomir Aujesky
Journal:  Am J Public Health       Date:  2006-10-31       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.